Helius Medical Technologies, Inc. to Release Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023
Helius Medical Technologies (NASDAQ: HSDT) has announced it will release its fourth quarter and full year 2022 financial results on March 9, 2023, after market close. The company's conference call will be hosted by CEO Dane C. Andreeff and CFO Jeffrey S. Mathiesen at 4:30 PM ET that same day. Helius focuses on innovative neuromodulation therapies for balance and gait deficits, with its main product, the Portable Neuromodulation Stimulator (PoNS), aimed at treating neurologic deficits. PoNS is indicated for use in patients with mild-to-moderate MS symptoms and authorized for sale in Canada and Australia for related conditions.
- Scheduled financial results release may provide insights into company performance and future growth.
- Conference call will discuss U.S. commercialization plans for PoNS, potentially boosting investor confidence.
- None.
NEWTOWN, Pa., March 06, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its fourth quarter and full year 2022 financial results on Thursday, March 9, 2023, after the market closes.
Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief Financial Officer will host a conference call to discuss the results and provide an expanded business update regarding Helius’ progress and plans surrounding the U.S. commercialization of PoNS® as follows:
| Date: | Thursday, March 9, 2023 |
| Time: | 4:30 p.m. Eastern Time |
| Register* (Audio Only): | Click Here |
| Webcast: | Click here |
The webcast will be archived under the Newsroom section of the Company’s investor relations website.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brain’s ability to compensate and promotes neuroplasticity, aiming to improve the lives of people dealing with neurologic diseases. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS). For more information, visit www.heliusmedical.com.
About the PoNS Device and PoNS Therapy
The Portable Neuromodulation Stimulator is an innovative non-surgical medical device, inclusive of a controller and mouthpiece, which delivers electrical stimulation to the surface of the tongue to improve balance and gait. The PoNS device is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from MS and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.
PoNS is also authorized for sale in Canada for two indications: (i) for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used in conjunction with physical therapy; and (ii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy. PoNS is also authorized for sale in Australia for short term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait. For more information visit www.ponstherapy.com.
Investor Relations Contact:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
FAQ
When will HSDT release its financial results for 2022?
What is the focus of Helius Medical Technologies?
What is the Portable Neuromodulation Stimulator (PoNS)?
Who will host the HSDT financial results conference call?
What time is the HSDT conference call scheduled for?
